Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. - Wikidata - awgldk - TriplyDB

Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody.

Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody.

http://www.wikidata.org/entity/Q33319628

about

Fc receptors and their influence on efficacy of therapeutic antibodies for treatment of viral diseases Henipavirus mediated membrane fusion, virus entry and targeted therapeutics Hendra virus Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets.Hendra virus and Nipah virus animal vaccines.A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection.Targeting of bone-derived insulin-like growth factor-II by a human neutralizing antibody suppresses the growth of prostate cancer cells in a human bone environment.Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection.Expecting the unexpected: nucleic acid-based diagnosis and discovery of emerging viruses.Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogens Human monoclonal antibody fragments binding to insulin-like growth factors I and II with picomolar affinity.Use of monoclonal antibodies against Hendra and Nipah viruses in an antigen capture ELISA A novel model of lethal Hendra virus infection in African green monkeys and the effectiveness of ribavirin treatment A functional henipavirus envelope glycoprotein pseudotyped lentivirus assay system.Evidence for henipavirus spillover into human populations in Africa.Detailed morphological characterisation of Hendra virus infection of different cell types using super-resolution and conventional imaging.Crystal structure of the Hendra virus attachment G glycoprotein bound to a potent cross-reactive neutralizing human monoclonal antibody.Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains.Henipavirus outbreaks to antivirals: the current status of potential therapeutics.Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies.Viral antibody dynamics in a chiropteran host.A treatment for and vaccine against the deadly Hendra and Nipah viruses Hendra and nipah infection: pathology, models and potential therapies.Emerging paramyxoviruses: molecular mechanisms and antiviral strategies Immunization strategies against henipaviruses Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody.A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.Ephrin-B2 and ephrin-B3 as functional henipavirus receptors Escape From Monoclonal Antibody Neutralization Affects Henipavirus Fitness In Vitro and In Vivo.Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines.Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.A recombinant Hendra virus G glycoprotein subunit vaccine protects nonhuman primates against Hendra virus challenge.Basic research in HIV vaccinology is hampered by reductionist thinking.Hendra virus: a one health tale of flying foxes, horses and humans.Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.Therapeutic antibodies as a treatment option for dengue fever.An Outdated Notion of Antibody Specificity is One of the Major Detrimental Assumptions of the Structure-Based Reverse Vaccinology Paradigm, Which Prevented It from Helping to Develop an Effective HIV-1 Vaccine.Henipavirus pathogenesis and antiviral approaches.Novel Functions of Hendra Virus G N-Glycans and Comparisons to Nipah Virus.

P2860

Q26783175-2A4A324D-D152-41D2-B801-D64F033911E8 Q27002511-1DF940BC-A8A4-4700-845E-98F7EE5C5DEB Q27006568-D4CF25CF-AAD6-463F-A6AA-7D1CC715C73F Q30357665-0A08C81F-8786-44D1-AE46-DC4ECFE22A19 Q30387821-D196E871-42E0-4CB0-A889-3B93F8E06106 Q33514831-1F4966CF-02A2-4943-AAC3-F73137F35374 Q33575740-BBAE4BD0-38EB-447E-8D53-241AD9F30D09 Q33587327-898F2F9D-F99F-4457-9566-6080C64C01D3 Q33890431-46C49118-0DD6-4436-9E72-6EC2D267BCF7 Q33946209-9715048F-39A3-4BCC-A62E-D97DDABF29B7 Q33959016-88D0DBAA-D0C7-48CB-AAB9-33F9DF97E334 Q33961230-875462A8-9550-4546-A7AE-91ADEB15187C Q34120677-DD200676-DE66-41E0-B702-57CF6D42E4A2 Q34365035-B6DDF4B9-34F3-46A9-91F5-6A9DA1403503 Q34541512-E474BFC0-3DB9-435B-A34D-6EBE24F84A58 Q34623407-E891F6BA-47EB-46A4-BACF-3700B229CFFD Q35018061-3C16DE59-8BF3-4AF9-848E-54CA2AB317E7 Q35033324-73EE27DE-5B04-40D4-A0C4-F421590ADC05 Q35141580-6760B0D3-0F6A-4AB8-BC9D-213BD317422A Q35260162-4A1EC8C0-4D66-43DD-9DF9-35A2120334AD Q35550671-8FE8100A-FF8E-47A4-8FB2-2AEE98BE9BDC Q35565878-1F3D97FF-39EB-40E1-ACAC-DC82394FDD73 Q35658146-6B21320E-8C9D-4A35-8A63-48ECC1D10495 Q35658152-E5B60C17-C26C-478B-8647-6F1EEFAE2415 Q35735589-260E601D-4C05-4D88-89C8-8C32E2EC2307 Q35741723-47E29871-5A8C-453D-B3C3-E18E214859F1 Q35855727-9CBF339B-70F8-433A-A006-E0E6B354ABF9 Q35881238-97C96833-B2A7-494B-977B-6C9C927AF8E7 Q35892085-E78D21B6-947D-4680-8B23-3B76CCE79DFB Q36440258-3A05F52A-3657-44B3-B63E-2BF1A77A848A Q36779713-AE73D7E0-F909-4C27-AC3B-0A16EE82A2DA Q37456354-D54B9381-6ED8-4D85-8F03-45B4262E1EDE Q37713970-5C8ECE71-6E84-4966-BFBF-0EEA4C056652 Q38025633-CAA9847D-A707-4726-8FFD-C2C134FDE5DD Q38093644-DE766174-865C-4671-B44A-4AF1F795CF32 Q38098075-10B66D05-F67E-42D8-8568-EF7668B6376E Q38149195-82C03E00-3C5B-47BC-B6D0-C266C81599DF Q38283531-A0F15009-35DA-4727-848A-F8D16C60B797 Q38337204-D6D48CC8-6997-4122-AB7F-A9DB716872D6 Q38878292-D03EE71A-7A35-41D0-ABED-0B20F7893ACB

P2860

Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody.

http://www.wikidata.org/entity/Q33319628

description

2008 nî lūn-bûn

@nan

2008 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մարտին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Exceptionally potent cross-rea ...... y a human monoclonal antibody.

@ast

Exceptionally potent cross-rea ...... y a human monoclonal antibody.

@en

Exceptionally potent cross-rea ...... y a human monoclonal antibody.

@nl

type

label

Exceptionally potent cross-rea ...... y a human monoclonal antibody.

@ast

Exceptionally potent cross-rea ...... y a human monoclonal antibody.

@en

Exceptionally potent cross-rea ...... y a human monoclonal antibody.

@nl

altLabel

Exceptionally potent cross-rea ...... by a human monoclonal antibody

@en

prefLabel

Exceptionally potent cross-rea ...... y a human monoclonal antibody.

@ast

Exceptionally potent cross-rea ...... y a human monoclonal antibody.

@en

Exceptionally potent cross-rea ...... y a human monoclonal antibody.

@nl

P1433

Q33319628-A9F48C8D-B4F8-4EB1-835A-25253EA5E73A

P1476

Q33319628-4D1441D9-85DE-4D24-9947-53BFEEED23B2

P2093

Q33319628-1E026B57-8A38-483F-8030-540909BABDF1

Q33319628-80883BE0-23E1-4C3E-A755-17C7FBCB85D4

Q33319628-852C9797-8A58-45A5-ADDE-5C61819D61EF

Q33319628-8D58AE50-1A8D-4378-A810-60469E47C295

Q33319628-9DAC0CCA-8970-4D11-AB61-288F3D40C025

Q33319628-AAE47C62-444A-4F2E-AE0F-14C2664594BA

Q33319628-D6B1A26A-3883-44CF-9A04-48B7B83D9C25

Q33319628-E0394376-D6E5-4215-A889-D8D949966D68

P304

Q33319628-EA32F37E-98AC-4509-A35D-A3A740AF70E2

P31

Q33319628-22B4ACFD-903A-40F3-BC4E-4F3283386F82

P356

Q33319628-CC584E59-236A-4EE6-8F21-F67DE5F0B182

P407

Q33319628-B6349656-9B68-4D22-AACB-418670B165B5

P433

Q33319628-7181A378-1691-48DD-B51E-563D07517E3F

P478

Q33319628-D9FE6104-4236-4106-9898-08D29C859FA1

P50

Q33319628-734BECBC-8ED8-4F55-86DA-DA40A4E95AB7

Q33319628-76D248F6-3425-45C4-BBA8-D57DD170DFB2

Q33319628-96C35547-D873-4ECF-8C68-929E9AC78D7B

P577

Q33319628-49FFE1B6-E913-43ED-977B-C3BB7072ED9B

P5875

Q33319628-63A77D3E-15D1-4339-9457-B13BDA5A175E

P698

Q33319628-986741E9-F213-47A7-8CF7-5A3CB6341B6C

P921

Q33319628-04C15520-B5C3-48EA-B04D-75ED2EC92CB1

Q33319628-80EAD55B-AFB3-4F51-A09F-02FF90D02715

Q33319628-9AD04CFB-2C3F-4709-9F10-60DC84367CE8

P356

P1433

The Journal of Infectious Diseases

P1476

Exceptionally potent cross-rea ...... y a human monoclonal antibody.

@en

P2093

Antony S Dimitrov

http://www.w3.org/2001/XMLSchema#string

Christopher C Broder

http://www.w3.org/2001/XMLSchema#string

Deborah Middleton

http://www.w3.org/2001/XMLSchema#string

Dimiter S Dimitrov

http://www.w3.org/2001/XMLSchema#string

Gary Crameri

http://www.w3.org/2001/XMLSchema#string

Kimberly A Bishop

http://www.w3.org/2001/XMLSchema#string

Yang Feng

http://www.w3.org/2001/XMLSchema#string

Zhongyu Zhu

http://www.w3.org/2001/XMLSchema#string

P304

846-853

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/528801

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

197

http://www.w3.org/2001/XMLSchema#string

P50

Katharine Bossart

P577

2008-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5579871

http://www.w3.org/2001/XMLSchema#string

P698

18271743

http://www.w3.org/2001/XMLSchema#string

P921